Catherine T. Doherty Net Worth

Track Major Insider Updates On X/Twitter

Last Updated: 4 months ago

Catherine T. Doherty has an estimated net worth of at least $34.3 million*, as of Oct. 29, 2025. They own 68,402 shares of DGX stock. They have sold 172,436 shares of DGX stock since 2021, for an estimated $22.2 million.

Catherine T. Doherty $DGX SEC Form 4 Insider Trading

Catherine T. Doherty has filed a total of 28 insider trades in $DGX since 2021. Their most recent trade was a sale of 1,433 shares, made on Feb 19, 2026. Their largest trade was a sale of 28,300 shares, made on Nov 27, 2024. We estimate that they now own 68,402 shares of $DGX, worth an estimated $12.1 million.

Insider Trading at $DGX

There have been a total of 124 insider trades reported at $DGX since 2021, with 0 shares purchased and 1.1 million shares sold. The most active insider traders in $DGX stock have been Michael E Prevoznik, Stephen H Rusckowski, and J. E. Davis. The most recent trade was a sale of 958 shares reported by Patrick Plewman (SVP for Diagnostic Services), made on Feb 19, 2026.

History of Insider Stock Trades by Catherine T. Doherty

Company Ticker	Purchase / Sale	Shares	Date	Disclosed (EST)
DGX	Sale	1,433	Feb 19, 2026	Feb. 20, 2026, 6:11 p.m.
DGX	Sale	10,573	Feb 13, 2026	Feb. 17, 2026, 5:37 p.m.
DGX	Sale	351	Feb 13, 2026	Feb. 17, 2026, 5:37 p.m.
DGX	Sale	1,619	Feb 13, 2026	Feb. 17, 2026, 5:37 p.m.
DGX	Sale	3,500	Feb 13, 2026	Feb. 17, 2026, 5:37 p.m.
DGX	Sale	10,122	Feb 13, 2026	Feb. 17, 2026, 5:37 p.m.
DGX	Sale	5,370	Mar 05, 2025	March 7, 2025, 8:23 p.m.
DGX	Sale	716	Mar 04, 2025	March 5, 2025, 5:38 p.m.
DGX	Sale	824	Feb 27, 2025	Feb. 28, 2025, 5:35 p.m.
DGX	Sale	899	Feb 20, 2025	Feb. 21, 2025, 5:41 p.m.
DGX	Sale	535	Feb 19, 2025	Feb. 21, 2025, 5:41 p.m.
DGX	Sale	4,803	Nov 27, 2024	Dec. 2, 2024, 5:41 p.m.
DGX	Sale	28,300	Nov 27, 2024	Dec. 2, 2024, 5:41 p.m.
DGX	Sale	1,187	Feb 29, 2024	March 1, 2024, 5:51 p.m.
DGX	Sale	5,557	Feb 28, 2024	March 1, 2024, 5:51 p.m.
DGX	Sale	821	Feb 22, 2024	Feb. 23, 2024, 5:32 p.m.
DGX	Sale	5,307	Mar 07, 2023	March 8, 2023, 5:38 p.m.
DGX	Sale	717	Mar 03, 2023	March 6, 2023, 6:08 p.m.
DGX	Sale	1,690	Feb 24, 2023	Feb. 27, 2023, 5:42 p.m.
DGX	Sale	17,358	Nov 28, 2022	Nov. 29, 2022, 5:35 p.m.
DGX	Sale	23,407	Nov 28, 2022	Nov. 29, 2022, 5:35 p.m.
DGX	Sale	7,032	Mar 08, 2022	March 9, 2022, 5:40 p.m.
DGX	Sale	2,750	Feb 24, 2022	Feb. 28, 2022, 8:50 p.m.
DGX	Sale	3,250	Nov 29, 2021	Dec. 1, 2021, 5:34 p.m.
DGX	Sale	15,908	Nov 29, 2021	Dec. 1, 2021, 5:34 p.m.
DGX	Sale	14,575	Nov 29, 2021	Dec. 1, 2021, 5:34 p.m.
DGX	Sale	300	Nov 29, 2021	Dec. 1, 2021, 5:34 p.m.
DGX	Sale	3,532	Nov 29, 2021	Dec. 1, 2021, 5:34 p.m.

$DGX Executives and Stock Owners with Insider Trades

Michael E Prevoznik, SVP & General Counsel
Stephen H Rusckowski, Chairman, CEO and President
J. E. Davis, CEO and President
Catherine T. Doherty, EVP, Regional Businesses
Patrick Plewman, SVP for Diagnostic Services
Catherine T. Doherty, SVP, Group Exec. Clin. Fran.
Karthik Kuppusamy, SVP, Clinical Solutions
Michael J Deppe, SVP, Corp. Controller & CAO
Catherine T. Doherty, SVP, Regional Businesses
Mark E Delaney, SVP & Chief Commercial Officer
Michael J Deppe, VP, Corp. Controller & CAO

*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.